KMT2A and acute myeloid leukemia: Secondary transplantation was performed by injecting 200,000 leukemic whole BM cells into sublethally irradiated (650 rads) congenic mice, which did not exhibit any survival difference (median survival; 23.5 vs 23 days, p = 0.848) (Supplementary Fig. 4d), demonstrating that Sharp1 deletion does not affect development or propagation of MLL-AF9 AML.